EXHIBIT 5, Tab G

G

APPROVED DRUG PRODUCTS with


THERAPEUTIC EQUIVALENCE EVALUATIONS LIBRA

24th EDITION

Cumulative Supplement 7

July 2004

CONTENTS



B-1

PAGE iü INTRODUCTION 1.0 iii How to Use the Cumulative Supplement 1.1 iv Applicant Name Changes..... 1.2 Ribavirin 200mg Oral Capsule..... ٧ 1.3 Levothyroxine Sodium. v 1.4 vì Availability of the Edition..... 1.5 vii Report of Counts for the Prescription Drug Product List..... 1.6 Cumulative Supplement Change Legend viii 1.7 DRUG PRODUCT LISTS 1-1 Prescription Drug Product List..... 2-1 OTC Drug Product List..... Drug Products with Approval under Section 505 of the Act 3-1 Administered by the Center for Biologics Evaluation and Research List..... Orphan Product Designations and Approvals List 4-1 Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution 5-1 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM A. Patent and Exclusivity Lists..... A-1

Please Note:

The 24th Edition of the Orange Book will be the last paper version. All the components of the paper Orange Book are and have been available on the Internet since 1997. Refer to the Introduction 1.3, Availability of the Edition, for specific locations. Additional details will be made available in future Cumulative Supplement publications.

B. Patent and Exclusivity Terms.....

| | RX DRUG PROD | UCT LIST - CUMULATIVE SUPPLME | NT 7 - July 2004 | 1-50 |
|----|-------------------------------------|-------------------------------|------------------------|---------------|
| | INJECTABLE: INJECTION | | | |
| | KETOROLAC TROMETHAMIN | E | | |
| AP | HOSPIRA | 30MG/ML | N74802 002 Jun 05, 1 | |
| AP | | 30MG/ML | N74993 002 Jan 27, 1 | 999 May CAHN |
| | TORADOL | | | |
| | @ ROCHE PALO | 15MG/ML | N19698 001 Nov 30, 1 | |
| | 9 | 30MG/ML | N19698 002 Nov 30, 1 | 989 Jan DISC |
| | KETOTIFEN FUMARATE | | | |
| | SOLUTION/DROPS; OPHTHAL ZADITOR | MIC | | |
| | + NOVARTIS | EQ 0.025% BASE | N21066 001 Jul 02, 1 | 999 Feb CAHN |
| | LABETALOL HYDROCHLORIDE | • | | |
| | INJECTABLE; INJECTION | | | |
| | LABETALOL HCL | | | |
| AP | HOSPIRA | 5MG/ML | N75239 001 Nov 29, 1 | |
| AP | | 5MG/ML | N75240 001 Nov 29, 1 | 999 May CAHN |
| | LAMIVUDINE | | | |
| | TABLET; ORAL | | | |
| | EPIVIR | | N20564 001 Nov 17, 1 | GGS May CRI.D |
| | GLAXOSMITHKLINE + | 150MG 300MG | N20564 003 Jun 24, 26 | |
| | LAMOTRIGINE | | | |
| | TABLET; ORAL | | | |
| | LAMICTAL | | | |
| | + GLAXOSMITHKLINE | 25MG | N20241 005 Dec 27, 19 | |
| | • | 200MG | N20241 003 Dec 27, 19 | 94 Apr CRLD |
| | LANSOPRAZOLE | | | |
| | FOR SUSPENSION, DELAYED | RELEASE; ORAL | | |
| | PREVACID TAP PHARM | 15MG/PACKET | N21281 001 May 03, 20 | 001 Jul CDFR |
| | + | 30MG/PACKET | N21281 002 May 03, 20 | |
| ÷ | FOR SUSPENSION, EXTENDE | | - | |
| | PREVACID | | | |
| | TAP PHARM | 15MG/PACKET | N21281 001 May 03, 20 | |
| | + | 30MG/PACKET | N21281 002 May 03, 20 | 01 Jul CDFR |
| | INJECTABLE: INTRAVENOUS PREVACID IV | | | |
| | + TAP PHARIM | 30MG/VIAL | N21566 001 May 27, 20 | 04 May NEWA |
| | TABLET, DELAYED RELEASE | , ORALLY DISINTEGRATING; ORAL | | |
| | PREVACID | 15MG | N21428 001 Aug 30, 20 | 02 Jul CDFR |
| | TAP PHARM | 30MG | N21428 002 Aug 30, 20 | |
| | | | • | |
| | TABLET, ORALELY DISINTEGE PREVACID | raling, orde | | |
| | TAP PHARIM | 15MG | N21428 001 Aug 30, 20 | 02 Jul CDFR |
| | + | 30MG | N21428 002 Aug 30, 200 | 02 Jul CDFR |
| , | LEFLUNOMIDE | | | |
| | TABLET; ORAL | | | |
| | ARAVA | 10000 | N20905 003 Sep 10, 199 | AS Jul CMFD |
| | @ AVENTIS IPHARMS | 100MG | 170 000 9eb 10, 133 | o ent cuth |

>A>
>A>
>A>
>A>
>A>
>D>
>D>
>D>
>D>
>D>

>A>
>A>
>A>
>A>
>A>
>D>
>D>
>D>
>D>
>D>

>D>

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLMENT 7 - July 2004

1-51

| | | W DROG PRODUCT | Digi Comomerate | | | | |
|---|----------|--------------------------------------|--------------------|--------------------------|--------------------|----------|---------|
| | | TABLET: ORAL | | | | | |
| | | ARAVA | | | | | |
| >A> | | + AVENTIS PHARMS | 100MG | N20905 00 | 3 Sep 10, | 1998 J | ul CMFD |
| | | LEUCOVORIN CALCIUM | | | | | |
| | | INJECTABLE; INJECTION | | | | | |
| | | LEUCOVORIN CALCIUM PRESERVATIVE FREE | | | | | |
| >D> | AP | BIGMAR | EQ 200MG BASE/VIAL | N40258 001 | | | |
| >D> | | + | EQ 500MG BASE/VIAL | N40286 001 | | | |
| >A> | AP | BIGMAR BIOREN PHARMS | EQ 200MG BASE/VIAL | N40258 001 | | | |
| >A> | | + | EQ 500MG BASE/VIAL | N40286 001 | | | |
| | AP | + HOSPIRA | EQ 10MG BASE/ML | N40147 001 | Jun 25, | 1997 M | ay CAHN |
| | | LEVOBUPIVACAINE HYDROCHLORIC | <u>E</u> | | | | |
| | | INJECTABLE; INJECTION CHIROCAINE | | | | | |
| | | @ PURDUE PHARMA LP | EO 2.5MG BASE/ML | N20997 001 | Aug 05, | 1999 M | ay DISC |
| | | 6 | EQ 5MG BASE/ML | N20997 002 | Aug 05, | 1999 M | ay DISC |
| | | e | EQ 7.5MG BASE/ML | N20997 003 | Aug 05, | 1999 M | ay DISC |
| | | LEVOCABASTINE HYDROCHLORIDE | | | | | |
| | | SUSPENSION/DROPS; OPHTHALM | ıc | | | | |
| | | LIVOSTIN + NOVARTIS | EQ 0.05% BASE | N20219 001 | Nov 10, | 1993 F | eb CAHN |
| | | LEVOFLOXACIN | | | | | |
| | | SOLUTION/DROPS: OPHTHALMIC | | | | | |
| | | IOUIX | | | | | |
| | | + SANTEN | 1.5% | N21571 001 | Mar 01, | 2004 Ma | ar NEWA |
| | | LEVONORGESTREL | | | | | |
| | | TABLET; ORAL | | | | | |
| | | PLAN B | | | | | |
| | | + DURAMED | 0.75MG | N21045 001 | Jul 28, | 1999 Fe | eb CAHN |
| | | LEVOTHYROXINE SODIUM | | | | | |
| | | TABLET; ORAL | | | | | |
| | | LEVOLET | | | | | |
| >A> | BX | VINTAGE | 0.025MG | N21137 001 | Jun 06, | | |
| <a<< td=""><td>BX</td><td></td><td>0.05MG</td><td>N21137 002</td><td>Jun 06, Jun 06,</td><td></td><td></td></a<<> | BX | | 0.05MG | N21137 002 | Jun 06, Jun 06, | | |
| >A> | BX | | 0.075MG | N21137 003 | Jun 06, | | |
| >A> | BX | | 0.088MG | N21137 004 N21137 005 | Jun 06, | | |
| >A> | BX | | 0.1MG | N21137 005 | Jun 06, | | |
| >A> | BX | | 0.112MG | N21137 007 | Jun 06, | | |
| >A> | BX | | 0.125MG | N21137 007 | Jun 06, | | |
| <a<< td=""><td>BX BX</td><td></td><td>0.137MG</td><td>N21137 000</td><td>Jun 06,</td><td></td><td></td></a<<> | BX BX | | 0.137MG | N21137 000 | Jun 06, | | |
| >A> | BX | | 0.15MG 0.175MG | N21137 010 | Jun 06, | | |
| >A> | BX | | 0.2MG | N21137 011 | Jun 06, | | |
| >A> | BX | | 0.3MG | N21137 012 | Jun 06, | | |
| >D> | BX | VINTAGE PHARMS | 0.025MG | N21137 001 | Jun 06, | | |
| >D> | BX | | 0.05MG | N21137 002 | Jun 06, | 2003 Ju | 1 CAHN |
| >D> | BX | | 0.075MG | N21137 003 | Jun 06, | 2003 Ju | 1 CAHN |
| >D> | BX | • | 0.088MG | N21137 004 | Jun 06, | | |
| >D> | BX | | 0.1MG | N21137 005 | Jun 06, | 2003 Ju | 1 CAHN |
| | | | | W04435 006 | T 0.6 | 2007 311 | I CAUN |

^{*}SEE PREFACE SECTION 1.4 LEVOTHRYROXINE SODIUM

N21137 006 Jun 06, 2003 Jul CAHN

0.112MG

>D>

BX